Trial Profile
Safety and efficacy of direct acting anti-viral therapies in octogenarian patients with chronic hepatitis C infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2018 New trial record
- 05 Jun 2018 Safety and efficacy results were presented at the Digestive Disease Week 2018.